Segment reporting (Tables)

9 Months Ended

May 31, 2025

Segment Reporting [Abstract]

Reconciliation of Operating Income (Loss) from Segments to Consolidated

The following table reflects results of operations of the Company’s reportable segments (in millions):

	Three months ended May 31,				Nine months ended May 31,
	2025		2024		2025		2024
Sales:
U.S. Retail Pharmacy
Pharmacy	$	24,381	$	21,812	$	72,524	$	65,704
Retail	6,334		6,691		19,437		20,604
Total	$	30,715	$	28,503	$	91,961	$	86,308
International
Pharmacy	$	913	$	874	$	2,662	$	2,698
Retail	1,976		1,839		6,274		5,928
Wholesale	3,283		3,014		9,721		8,955
Total	$	6,172	$	5,727	$	18,657	$	17,581
U.S. Healthcare	$	2,102	$	2,125	$	6,427	$	6,232
Corporate and Other 1	$	(4)	$	(3)	$	(12)	$	(9)
Walgreens Boots Alliance, Inc.	$	38,986	$	36,351	$	117,034	$	110,111
Adjusted operating income:
U.S. Retail Pharmacy	$	350	$	501	$	1,278	$	1,947
International	214		175		615		562
U.S. Healthcare	54		(22)		196		(151)
Corporate and Other	(60)		(42)		(152)		(158)
Walgreens Boots Alliance, Inc.	$	558	$	613	$	1,936	$	2,200

1.Includes certain eliminations.

The following table reconciles adjusted operating income to Operating income (loss) (in millions):

	Three months ended May 31,				Nine months ended May 31,
	2025		2024		2025		2024
Adjusted operating income (Non-GAAP measure)	$	558	$	613	$	1,936	$	2,200
Acquisition-related amortization	(226)		(266)		(746)		(811)
Impairment of goodwill, intangibles and long-lived assets	(89)		—		(5,432)		(13,091)
Footprint optimization	(73)		—		(473)		—
Acquisition and disposition-related costs	(62)		(68)		(260)		(480)
Certain legal and regulatory accruals and settlements	(49)		(52)		(656)		(376)
Adjustments to equity earnings in Cencora	(13)		(57)		(122)		(129)
Transformational cost management	(3)		(95)		9		(401)
LIFO provision	10		36		(14)		(11)
Operating income (loss) (GAAP)	$	53	$	111	$	(5,759)	$	(13,099)